Primary Plasma Cell Leukemia algorithm from Dr. Samer Al Hadidi: myopenmedicine.com/algorithms/p...
Primary Plasma Cell Leukemia
myopenmedicine.com
Kate Sears
@katesears.bsky.social
Hi I'm Kate, community lead for Open Medicine. We make expert medical knowledge easy to access so clinicians can offer the best treatment for their patients. myopenmedicine.com
Newly Diagnosed Philadelphia Chromosome–Positive ALL: Frontline TKI Selection, Early Blinatumomab, MRD, and Allo-HCT Decision-Making algorithm from @talhabadarmd.bsky.social: myopenmedicine.com/algorithms/n...
Newly Diagnosed Philadelphia Chromosome–Positive ALL:Frontline TKI Selection, Early Blinatumomab, MRD, and Allo-HCT Decision-Making
myopenmedicine.com
AMPLITUDE: Niraparib + Abiraterone/Prednisone + ADT in HRR-Altered mCSPC algorithm from @drnataliagandur.bsky.social: myopenmedicine.com/algorithms/a...
AMPLITUDE: Niraparib + Abiraterone/Prednisone + ADT in HRR-Altered mCSPC
The algorithm is broadly aligned with current mCSPC practice for diagnosis, early treatment intensification with AR pathway inhibitors, and routine consideration of germline/somatic testing. However, ...
myopenmedicine.com
Adjuvant RCC After Nephrectomy: Risk, Surveillance, Pembrolizumab, and the Pembro/Belzutifan Decision from @drchoueiri.bsky.social: myopenmedicine.com/algorithms/a...
Adjuvant RCC After Nephrectomy: Risk, Surveillance, Pembrolizumab, and the Pembro/Belzutifan Decision
myopenmedicine.com
Stage I Testicular Germ Cell Tumors After Orchiectomy: Surveillance, Adjuvant Therapy, and Risk-Adapted Follow-Up algorithm from @drnataliagandur.bsky.social: myopenmedicine.com/algorithms/s...
Stage I Testicular Germ Cell Tumors After Orchiectomy: Surveillance, Adjuvant Therapy, and Risk-Adapted Follow-Up
This algorithm is broadly aligned with contemporary stage I testicular GCT management: confirm true clinical stage I with appropriate post-orchiectomy marker kinetics and imaging, then select surveill...
myopenmedicine.com
Newly Diagnosed Non-APL Acute Myeloid Leukemia: Initial Treatment Selection from @talhabadarmd.bsky.social: myopenmedicine.com/algorithms/n...
Newly Diagnosed Non-APL Acute Myeloid Leukemia: Initial Treatment Selection
This algorithm is broadly aligned with contemporary adult non-APL AML practice: urgent exclusion of APL and stabilization, early comprehensive cytogenetic/molecular profiling, fitness-based selection ...
myopenmedicine.com
TALAPRO-3: Talazoparib + Enzalutamide + ADT in HRR-Altered mCSPC from @neerajagarwal.bsky.social @drnataliagandur.bsky.social: myopenmedicine.com/algorithms/t...
TALAPRO-3: Talazoparib + Enzalutamide + ADT in HRR-Altered mCSPC
The algorithm is broadly aligned with current mCSPC practice in emphasizing ADT as backbone therapy, recommending treatment intensification, and incorporating germline/somatic testing to guide therapy...
myopenmedicine.com
Nice use of the living algorithm format. The piece that trips people up in platinum sensitive relapse is maintenance selection after response, since prior PARP exposure in front line increasingly limits repeat PARP and pushes the BRCA and HRD conversation earlier.
Yesterday, the @fda.gov approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer. This action is based on results from the ASCENT-03 & -04 global clinical trials, which @stolaney1.bsky.social helped to lead. ➡️ bit.ly/4uZoDP0
Management of Platinum-Sensitive Recurrent Ovarian Cancer from Dr. Kathleen Moore at @unmc.bsky.social: myopenmedicine.com/algorithms/m...
Management of Platinum-Sensitive Recurrent Ovarian Cancer
myopenmedicine.com
Really clean framework. The hinge most trainees underweight is daratumumab-refractory versus not, since that one branch reroutes everything toward carfilzomib pairings or BCMA-directed therapy earlier. Good to see the len-refractory pathway called out too, since that is the real-world default now.
Systemic Therapy Selection for Metastatic Pheochromocytoma and Paraganglioma algorithm from Dr. Michael Glover at @mdanderson.bsky.social: myopenmedicine.com/algorithms/s...
Systemic Therapy Selection for Metastatic Pheochromocytoma and Paraganglioma
The algorithm is broadly aligned with contemporary management of metastatic PPGL by emphasizing symptom stabilization, careful selection between observation vs treatment, and use of functional imaging...
myopenmedicine.com
First-line Advanced/Metastatic Squamous NSCLC: HARMONi-6 based Treatment Selection from Drs. Ben Bleiberg and Charu Aggarwal at @pennmedicine.bsky.social: myopenmedicine.com/algorithms/f...
First-line Advanced/Metastatic Squamous NSCLC: HARMONi-6 based Treatment Selection
The algorithm is broadly aligned with current first-line management of advanced/metastatic squamous NSCLC: universal biomarker testing, PD-L1–informed selection, and chemoimmunotherapy as the dominant...
myopenmedicine.com
Management of 1st Relapse Multiple Myeloma from Dr. Rajshekhar Chakraborty at @cuimcmedicinedept.bsky.social: myopenmedicine.com/algorithms/m...
Management of 1st Relapse Multiple Myeloma
myopenmedicine.com
Newly Diagnosed Myeloma algorithm from @vincentrk.bsky.social: myopenmedicine.com/algorithms/n...
Newly Diagnosed Myeloma
Treatment algorithm for newly diagnosed myeloma patients. Dr. Rajkumar is a contributing editor to the International Myeloma Foundation (https://www.myeloma.org/frontline-treatment-options).
myopenmedicine.com
STK11/KEAP1 Advanced/Metastatic Squamous NSCLC algorithm from Drs. Charu Aggarwal and Ben Bleiberg @pennmedicine.bsky.social: myopenmedicine.com/algorithms/s...
STK11/KEAP1 Advanced/Metastatic Squamous NSCLC
The algorithm is partially aligned with current metastatic squamous NSCLC practice in its emphasis on broad molecular testing and guideline-directed targeted therapy when actionable drivers are presen...
myopenmedicine.com
Second-line / Previously Treated Metastatic Pancreatic Cancer (mPDAC) from @mpishvaian.bsky.social: myopenmedicine.com/algorithms/s...
Second-line / Previously Treated Metastatic Pancreatic Cancer (mPDAC)
The algorithm is broadly aligned with current practice for previously treated metastatic PDAC in emphasizing performance status assessment, clinical trial enrollment, molecular profiling, and use of e...
myopenmedicine.com
Advanced Dedifferentiated Liposarcoma: Systemic Therapy from Dr. Michael Wagner at @danafarber.bsky.social: myopenmedicine.com/algorithms/a...
Advanced Dedifferentiated Liposarcoma: Systemic Therapy
myopenmedicine.com
First-Line Metastatic Urothelial Carcinoma: EV + Pembrolizumab vs Platinum-Based Therapy from @drnataliagandur.bsky.social: myopenmedicine.com/algorithms/f...
First-Line Metastatic Urothelial Carcinoma: EV + Pembrolizumab vs Platinum-Based Therapy
This algorithm (1L Metastatic Urothelial Carcinoma: EV/Pembro vs Platinum) should answer one practical question: In a patient with previously untreated unresectable or metastatic urothelial carcinoma,...
myopenmedicine.com
IBCG Risk Stratification Model for Intermediate-Risk NMIBC from @ashishkamatmd.bsky.social: myopenmedicine.com/algorithms/i...
IBCG Risk Stratification Model for Intermediate-Risk NMIBC
Intermediate-Risk Non–Muscle-Invasive Bladder Cancer (IR NMIBC) Risk Stratification Model by the International Bladder Cancer Group (IBCG).
myopenmedicine.com
@IyerGopa @MSKCancerCenter with phase 1 #NEXUS01 of nectin4 delivering topoisomerase inhibitor — ligand is still relevant for some EV-pembro refectory #bladdercancer w responses. @asco #ASCO26 @oncoalert @urotoday
First line Metastatic Castration-Resistant Prostate Cancer (mCRPC) from Dr. Fred Saad: myopenmedicine.com/algorithms/f...
First line Metastatic Castration-Resistant Prostate Cancer (mCRPC)
myopenmedicine.com
Early and Advanced Triple Negative Breast Cancer (TNBC) from @ilanaschlam.bsky.social: myopenmedicine.com/algorithms/e...
Early and Advanced Triple Negative Breast Cancer (TNBC)
Post ASCO, ESMO and SABCS 2025 TNBC algorithm. Radiation is indicated for some with early stage disease. Add Zometa for postmenopausal patients, q6 months for 2-3 years (Early stage).*Keynote522 studi...
myopenmedicine.com
RET fusion–positive NSCLC: evolving adjuvant and metastatic targeted therapies from Dr. Gilberto Lopes at Sylvester Comprehensive Cancer Center: myopenmedicine.com/algorithms/r...
RET fusion–positive NSCLC: evolving adjuvant and metastatic targeted therapies
The metastatic portion is broadly aligned with current standards: comprehensive RET fusion testing at diagnosis and first-line selective RET inhibition (selpercatinib or pralsetinib) is guideline-conc...
myopenmedicine.com
Managing radiation toxicity abdominal pain and cramping on @openmedicine.bsky.social from Dr. Nina Sanford at UT Southwestern: myopenmedicine.com/algorithms/m...
Managing radiation toxicity abdominal pain and cramping
How Dr. Nina Sanford, Associate Professor and Chief of Gastrointestinal Radiation at UT Southwestern manages abdominal pain and cramping after radiation therapy (RT). Originally posted on YouTube 'Man...
myopenmedicine.com
Today, we honor and remember the brave men and women who made the ultimate sacrifice in service to our country. 🇺🇸 Their courage and legacy will never be forgotten. #MemorialDay #HonorAndRemember #NeverForget
Metastatic clear cell RCC first-line treatment selection algorithm from @drchoueiri.bsky.social: myopenmedicine.com/algorithms/m...
Metastatic clear cell RCC first-line treatment selection
Algorithm for selection of first-line treatment for patients with metastatic clear cell RCC (mccRCC). The National Comprehensive Cancer Network, European Association of Urology, and European Society o...
myopenmedicine.com
PSMAfore: Taxane-naive PSMA-positive mCRPC after one prior ARPI progression algorithm from Prof. Karim Fizazi: myopenmedicine.com/algorithms/p...
PSMAfore: Taxane-naive PSMA-positive mCRPC after one prior ARPI progression
myopenmedicine.com
Now online in Cancer Discovery @aacrjournals.bsky.social: Senescent-like Neutrophils Shape Angiogenic Immunosuppressive Niches in CRC Liver Metastasis - by Zhihang Chen, Xiaoxue Ren, Yifan Zhang, Youmei Kang, Ye Yang, Xiaoxing Li, Jianting Long, Lixia Xu, Ming Kuang, et al. doi.org/10.1158/2159...
EGFR-driven stage IV NSCLC treatment pathways from @stephenvliu.bsky.social: myopenmedicine.com/algorithms/e...
EGFR-driven stage IV NSCLC treatment pathways
Treatment algorithm for stage IV metastatic non–small cell lung cancer (NSCLC) when biomarker testing confirms EGFR mutation, then a biomarker specific approach is used. Treatment selection is guided ...
myopenmedicine.com